Lupron Lawsuit Lawyers for Stroke, Blood Clot, Heart Attack Injury Claims
Study Finds Link Between Lupron and an Increased Risk for Cardiovascular Events
A study published earlier this year in the journal Circulation from the American Heart Association indicates that hormone therapy might increase the risk for cardiovascular events in gender-transitioning patients. Researchers analyzed the medical records of close to 3,900 patients living in the Netherlands and found a potential link between hormone therapy and blood clots, heart attack, and stroke.
Scientific research conducted in the past has already demonstrated an increased risk for cardiovascular events in patients taking hormones to relieve symptoms of menopause. However, little research has been conducted to date regarding the potential for higher incidence of cardiovascular events in patients receiving hormone therapy as part of gender transitioning. These patients are generally younger than patients experiencing menopause, but they also might have outside stressors not felt by menopausal patients, according to the authors of the Circulation article.
Cardiovascular Events Significantly Elevated in Transgender Patients Receiving Hormone Therapy
The researchers in this study examined medical records for 2,517 Dutch transgender women (individuals assigned male sex at birth and transitioning to female) taking estrogen and 1,358 Dutch transgender men (individuals assigned female sex at birth and transitioning to male) taking testosterone. The transgender woman had a median age of 30, while the transgender men had a median age of 23. The records spanned from 1972 to 2015, and patients were followed for eight or nine years, noting cardiovascular events occurring during this time.
Compared to the general female population, the transgender women in the study experienced twice as many strokes, five times as many blood clots, and more than twice as many heart attacks. Compared to the general male population, the transgender woman experienced almost double the number of strokes and more than four times as many blood clots. Compared to the general female population, the transgender men in the study experienced more than three times as many heart attacks.
Researchers Acknowledge Study Limitations, Urge Consideration of Other Risk Factors
The study authors stated that this analysis did not take into account other medical conditions and outside factors that can also increase a person’s risk for cardiovascular events. Factors not considered in the study included diet, smoking, exercise, and psychosocial stressors. However, the researchers concluded that hormone therapy could be contributing to cardiovascular events in transitioning patients.
Estrogen therapy has previously been shown to contribute to inflammation of the blood vessels and blood clotting, which could be why transgender women had higher incidence of deep vein thrombosis and stroke, the authors said. Likewise, testosterone therapy has previously been associated with a higher concentration of red blood cells and higher cholesterol, which might explain the higher incidence of heart attack in transgender men.
While the study considered only medical records, the rate of cardiovascular events in transitioning patients taking hormone therapy is something to which doctors and patients should pay careful attention, the authors said. The researchers advised doctors and patients to consider risk factors already present and to make attempts to mitigate those risks, if possible, before beginning hormone therapy. Patients will then need to be monitored for possible indicators of deep vein thrombosis, heart attack, and stroke.
“In light of our results, we urge both physicians and transgender individuals to be aware of this increased cardiovascular risk,” said Nienke Nota, M.D., one of the study’s authors and researcher with the Amsterdam University Medical Center. “It may be helpful to reduce risk factors by stopping smoking, exercising, eating a healthy diet and losing weight, if need before starting therapy, and clinicians should continue to evaluate patients on an ongoing basis thereafter.”
Patients engaging in hormone therapy who have suffered from cardiovascular-related ailments may be entitled to compensation.
At Montlick & Associates, We Know What it Takes to Win™ Product Liability Cases.
If you suffered an ailment or if you lost a loved one due to hormone therapy, contact Montlick and Associates, Attorneys at Law, today for your Free Consultation with our Product Liability Attorneys. You may be entitled to valuable compensation, including compensation for medical expenses, lost wages, Pain and Suffering, and more. Call us nationwide toll-free, 24 hours a day, 7 days a week at 1-800-LAW-NEED (1-800-529-6333), or by dialing #WIN (#946) from your cell phone. Or feel free to visit us visit us online at www.montlick.com and complete our Free Case Evaluation Form or our 24-hour live Online Chat.